MX2020008488A - Forma cristalina del derivado de oxopicolinamida y metodo de preparacion del mismo. - Google Patents

Forma cristalina del derivado de oxopicolinamida y metodo de preparacion del mismo.

Info

Publication number
MX2020008488A
MX2020008488A MX2020008488A MX2020008488A MX2020008488A MX 2020008488 A MX2020008488 A MX 2020008488A MX 2020008488 A MX2020008488 A MX 2020008488A MX 2020008488 A MX2020008488 A MX 2020008488A MX 2020008488 A MX2020008488 A MX 2020008488A
Authority
MX
Mexico
Prior art keywords
preparation
crystalline form
oxopicolinamide
derivative
oxopicolinamide derivative
Prior art date
Application number
MX2020008488A
Other languages
English (en)
Other versions
MX394495B (es
Inventor
Likun Wang
Zhenxing Du
Qiyun Shao
Lin Wang
Junran Yang
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2020008488A publication Critical patent/MX2020008488A/es
Publication of MX394495B publication Critical patent/MX394495B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Se proporcionan una forma cristalina de un derivado de oxopicolinamida y un método de preparación de la misma. En particular, se proporcionan formas cristalinas A, B, C, D, E y F de un compuesto como se muestra en la fórmula (I) y un método de preparación de las mismas. Las formas cristalinas A, B, C, D, E y F del compuesto de fórmula (I) obtenido en la presente descripción tienen buena estabilidad cristalina y estabilidad química, y se puede usar mejor en el tratamiento clínico.(VER FORMULA).
MX2020008488A 2018-02-27 2019-02-26 Forma cristalina del derivado de oxopicolinamida y metodo de preparacion del mismo MX394495B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810163529 2018-02-27
PCT/CN2019/076132 WO2019165951A1 (zh) 2018-02-27 2019-02-26 一种氧代吡啶酰胺类衍生物的晶型及其制备方法

Publications (2)

Publication Number Publication Date
MX2020008488A true MX2020008488A (es) 2022-08-04
MX394495B MX394495B (es) 2025-03-24

Family

ID=67804814

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008488A MX394495B (es) 2018-02-27 2019-02-26 Forma cristalina del derivado de oxopicolinamida y metodo de preparacion del mismo

Country Status (13)

Country Link
US (1) US11299462B2 (es)
EP (1) EP3741746A4 (es)
JP (1) JP2021514944A (es)
KR (1) KR20200127196A (es)
CN (1) CN111094241B (es)
AU (1) AU2019227332A1 (es)
BR (1) BR112020016856A2 (es)
CA (1) CA3091528A1 (es)
MX (1) MX394495B (es)
RU (1) RU2020125154A (es)
TW (1) TWI802654B (es)
UA (1) UA126251C2 (es)
WO (1) WO2019165951A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022003649A (es) * 2019-09-27 2022-06-08 Shenzhen Salubris Pharm Co Ltd Inhibidores del fxia y metodo de preparacion de los mismos y uso farmaceutico de los mismos.
WO2023208169A1 (zh) * 2022-04-29 2023-11-02 江苏恒瑞医药股份有限公司 一种凝血XIa抑制剂的离子液体

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7453002B2 (en) * 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
CN104136431B (zh) * 2011-12-21 2017-03-15 小野药品工业株式会社 作为凝血因子XIa抑制剂的吡啶酮和嘧啶酮衍生物
WO2014160592A2 (en) * 2013-03-27 2014-10-02 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
TWI633089B (zh) * 2013-03-28 2018-08-21 拜耳製藥股份有限公司 經取代的酮基吡啶衍生物
WO2015063093A1 (de) 2013-10-30 2015-05-07 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
CN105829298B (zh) * 2014-02-14 2019-02-01 四川海思科制药有限公司 一种吡啶酮或嘧啶酮衍生物、及其制备方法和应用
CN105658641B (zh) * 2014-07-25 2018-04-17 江苏恒瑞医药股份有限公司 氮茚‑酰胺类衍生物、其制备方法及其在医药上的应用
EP3197889B1 (de) * 2014-09-24 2018-08-01 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
CN106687458B (zh) 2014-09-24 2020-10-27 拜耳制药股份公司 取代的氧代吡啶衍生物
HUE057289T2 (hu) 2016-08-31 2022-05-28 Jiangsu Hengrui Medicine Co Oxopikolinamid-származék, annak elõállítási módszere és gyógyszerészeti felhasználása

Also Published As

Publication number Publication date
US20200385353A1 (en) 2020-12-10
TWI802654B (zh) 2023-05-21
KR20200127196A (ko) 2020-11-10
CA3091528A1 (en) 2019-09-06
EP3741746A4 (en) 2020-12-16
TW201936580A (zh) 2019-09-16
JP2021514944A (ja) 2021-06-17
CN111094241B (zh) 2022-06-21
WO2019165951A1 (zh) 2019-09-06
MX394495B (es) 2025-03-24
AU2019227332A1 (en) 2020-08-27
BR112020016856A2 (pt) 2020-12-22
US11299462B2 (en) 2022-04-12
EP3741746A1 (en) 2020-11-25
UA126251C2 (uk) 2022-09-07
RU2020125154A (ru) 2022-03-28
CN111094241A (zh) 2020-05-01

Similar Documents

Publication Publication Date Title
CO2019002596A2 (es) Un esteroide 19-nor-c21-n-pirazolilo c3,3-disustituido cristalino
MX377277B (es) Derivados de fenoximetilo.
CY1123689T1 (el) Κρυσταλλικη μορφη ελευθερης βασης λορλατινιβης
EA201591497A1 (ru) Новые производные октагидропирроло[3,4-c]пиррола и их аналоги в качестве ингибиторов аутотаксина
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
UY36999A (es) Derivados de aryl oxadiazol fungicidas
MX2017014809A (es) Amidas heterociclicas como inhibidores de cinasa.
EP4585268A3 (en) Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
EA201891622A1 (ru) Новые производные аммония, способ их получения и фармацевтические композиции, содержащие их
UA113643C2 (xx) N-цикліламіди як нематоциди
EA201691799A1 (ru) Бициклические соединения в качестве ингибиторов продукции аутотаксина (atx) и лизофосфатидиловой кислоты (lpa)
JO3592B1 (ar) شكل بلوري جديد لمشتق بنزيميدازول وطريقة تحضيره
EA201600091A1 (ru) 4-членные кольцевые карбоксамиды, применяемые в качестве нематоцидов
UY34104A (es) ?compuestos derivados benzamídicos heterocíclicos, procesos e intermedios para su preparación, composiciones y métodos para su uso?.
MX382166B (es) Compuestos de indazol como inhibidores de cinasa fgfr, preparacion y uso de los mismos.
EA201591349A1 (ru) Способ получения вортиоксетина
CO2019011980A2 (es) Formas cristalinas de (s)-afoxolaner
EA201991241A1 (ru) Способ получения метоксиметилпиридин дикарбоксилата
CY1125355T1 (el) Πεντακυκλικη ενωση
MX2022000243A (es) Nuevos compuestos heterociclicos.
CL2020000217A1 (es) Inhibidores de ror gamma.
MX2020008488A (es) Forma cristalina del derivado de oxopicolinamida y metodo de preparacion del mismo.
AR098592A1 (es) Formas cristalinas de 1-[4-(piridin-2-iloxi)-ciclohexil]-5,6-dihidro-4h-2,3,5,10b-tetraaza-benzo[e]azulenos
AR101951A1 (es) Síntesis de ent-progesterona e intermediarios de la misma
EA201692246A1 (ru) Способ получения 2,6-диметилбензохинона